Affimed spurs promising response numbers in NK cell study, but durability will be the big question

German biotech Affimed caught some attention earlier this year with a pair of complete responses in an early study of its NK cell regimen for lymphoma. The biotech is back with more data from that study, and the results look promising — but will durability hold up?

A combination...

Click to view original post